Observing Zongertinib Use in Japanese Patients With HER2-Mutated Lung Cancer
Studies zongertinib's real-world safety and effectiveness in adults with HER2-mutated lung cancer.
Plain-language title generated from the registry record
Registry title: Real-world Outcome of Zongertinib in Japan (J-HERZ)
Key facts
- Where
- Tokyo, JapanSee the site
Where in Japan
- Nippon Boehringer Ingelheim Co., Ltd.Tokyo, JapanNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Boehringer Ingelheim
- Trial code
- NCT07926308
- Record updated
- 9 November 2026
- Original description
This study aims to evaluate the real-world effectiveness and safety of zongertinib across treatment lines and human epidermal growth factor receptor 2 (HER2) mutation subtypes in Japanese patients with HER2-mutated non-small cell lung cancer (NSCLC).Read full original descriptionShow less
Observational Study of Zongertinib in Patients With HER2-mutated NSCLC in Japan (J-HERZ)
This study aims to evaluate the real-world effectiveness and safety of zongertinib across treatment lines and human epidermal growth factor receptor 2 (HER2) mutation subtypes in Japanese patients with HER2-mutated non-small cell lung cancer (NSCLC).
Inclusion: Patients aged ≥18 years; Patients with metastatic or locally advanced non-small cell lung cancer (NSCLC); Patients confirmed to be human epidermal growth factor receptor 2 (HER2) mutation-positive, as documented by a medical institution; Patients who have received or are scheduled to receive zongertinib based on the package insert; Patients who provided consent to participate in the study on or after the date of approval of the study conduct at each participating institution, through one of the following procedures:; Patients who, or whose legally acceptable representative, provided written informed consent for participation B) For patients transferred to another hospital, written informed consent is not mandatory, and registration through verbal informed consent will be permitted C) Patients for whom written or verbal informed consent cannot be obtained because they are deceased or cannot be contacted by the investigators can be enrolled through an opt-out procedure.
Exclusion: Patients who have received zongertinib as an investigational drug; Patients for whom first-time zongertinib treatment is on or after fourth line (4L) treatment.